Medicare to cover early Alzheimer's blood tests starting 2028
S. 3267 — ASAP Act · Filed by Susan Collins (R-ME) · 48 cosponsors · Introduced Nov 20, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare law to cover blood-based screening tests for early-stage Alzheimer's disease and related dementias, effective January 1, 2028. The tests must be FDA-cleared, classified, or approved, and include genomic sequencing, protein analysis, or other biomarker tests the Secretary deems equivalent. Medicare will pay for these tests as a covered service.
Why we flagged it
The bill's operative mechanism is straightforward: it adds a new category of preventive screening tests to Medicare's covered services. This is a standard coverage amendment, not a carve-out or restriction.
What the text implies
- The Secretary has broad discretion to define 'equivalent' tests beyond the listed categories (genomic sequencing, protein expression, imaging), potentially expanding coverage scope without further legislative action.
- Effective date of January 1, 2028 creates a 3-year lag before coverage begins, during which test developers and manufacturers may accelerate FDA submissions and market positioning.
The full analysis lists 4 implications of this text.
Who stands to gain
in vitro diagnostic (IVD) manufacturers producing blood biomarker tests; genomic sequencing companies; clinical laboratory service providers